Leo Pharma looking for pediatric patients for eczema trial
In a new phase II study, Leo Pharma wants to investigate the possibility of lowering the age requirements for atopic eczema drug Adtralza.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
In October last year, Leo Pharma demonstrated positive phase III data for Adtralza (tralokinumab) in atopic eczema patients aged 12–17. The company is now ostensibly trying to demonstrate that the injection treatment is safe for an even younger audience, according to a recent filing on database Clinical Trials.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst predicts slow start for Leo Pharma's Adtralza in UK
For subscribers
.jpg&w=384&q=75)
